We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value.
Second quarter & Half year 2022 results
Investors Event Calendar
Environmental, Social and Governance (ESG)
ESG Updates: July 20, 2022 (PDF 0.4 MB) | Apr 27, 2022 (PDF 0.7 MB) | Feb 03, 2022 (PDF 1.7 MB) | Oct 27, 2021 (PDF 0.5 MB)
Latest updates: Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessment
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
Media Releases
Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer
Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
Pulse Updates
December 16, 2021
Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease
September 28, 2021
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
Investor Relations Contacts
For questions about investor relations or the share registry, please contact our team.
Stay Up-to-Date
Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland